If you have certain forms of breast cancer, your doctor might suggest Kadcyla (ado-trastuzumab emtansine) as a treatment option. It’s a prescription drug used to treat HER2-positive (HER2+) breast ...

All of the women in the study had progressed on two or more HER2-targeted therapies, including Herceptin (trastuzumab) and Tykerb (lapatinib). Kadcyla (ado-trastuzumab emtansine; T-DM1) reduced the ...

Kadcyla outperformed Herceptin regarding overall- and invasive disease-free survival in patients with HER2-positive early breast cancer that still had remaining invasive disease after undergoing ...

The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer The ...

The Food and Drug Administration (FDA) has approved Kadcyla (ado-trastuzumab emtansine; Genentech) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual ...

– Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date – – Long-term data also showed continued benefit in invasive ...

Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE. The row over Kadcyla has lasted three years, and has been one of the ...

On the news, Kadcyla in this setting is now approved in 27 countries worldwide. The European Commission has approved Roche’s Kadcyla (trastuzumab emtansine) for the adjuvant (after surgery) treatment ...

The FDA approval of Roche/Genentech's breast cancer drug T-DM1 (brand name Kadcyla) last week has caused a mixed reaction from healthcare analysts. The FDA approval of Roche/Genentech’s breast cancer ...

Roche’s Kadcyla needs some oomph, and the Swiss drugmaker’s new data might just do the trick. The company is teeing up a new filing for its next-generation breast cancer drug, hoping to gin up more ...

Enhertu (trastuzumab deruxtecan), a HER2-targeting antibody-drug conjugate (ADC) bearing a deruxtecan (TOP1 inhibitor) warhead, was developed by Japanese pharmaceutical company Daichi Sankyo. A ...

– Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date – SOUTH SAN FRANCISCO, Calif. — Genentech, a member of the ...